Korea Blocks 432 Illegal Online Drug Listings — 82.4% Were on General Marketplaces

Korea's Ministry of Food and Drug Safety (MFDS), working with the Korean Pharmaceutical Association and other bodies, requested access blocks on 432 illegal drug sales and advertising listings found in violation of the Pharmaceutical Affairs Act. Of those, 222 came from routine monitoring and 210 from a recent focused inspection.

Where the Violations Were Found

The distribution channels matter more than the total.

• 82.4% of flagged channels were general shopping malls — not dedicated illicit sites, but the marketplaces ordinary consumers already use.
• Many were overseas sales sites, including Japanese pharmaceutical products.
• By category, digestive medications at 49.0% and eye drops at 34.8% dominated.

That those two categories lead is not accidental. Both are products travelers buy abroad, recommend in online reviews, and widely assume can be purchased without a prescription. Demand attracts sellers, and sellers attract advertising.

The Regulator's Warning

MFDS cited risks of counterfeiting, degradation, and contamination in online-distributed medication, along with uncertain safety and efficacy and the difficulty of obtaining remedy when harm occurs. Its guidance: medication should be taken only under prescription and dispensing from a hospital or pharmacy.

What This Means for Commerce Teams

The number that touches daily operations is 82.4% on general marketplaces. If you run an open marketplace or a brand store, this is not someone else's problem.

For Marketplace Operators

• Filter overseas-purchase category listings. Sweep for product names like "Japanese digestive medicine." Ingredient-based filters catch more than title-based ones.
• Review efficacy claims on product pages. Non-pharmaceutical products that describe drug-like effects fall under a separate regulatory exposure.
• Notify sellers at onboarding. Many violations come from sellers who simply do not know the rule. Screening at listing time costs less than post-hoc blocking.

For Advertising Teams

• Check the boundary between health supplement and pharmaceutical claims at the creative level. Passing a platform's ad review is not the same as complying with the law.
• Language used by influencers and in review content can fall within the advertiser's responsibility.

Regulatory requirements pushing down to the individual creative is a broader pattern — see Snapchat Adds Disclaimer Links to Pharma Ads.

Blocking is a remedy after the fact. The 222 cases from routine monitoring suggest this is a continuing program, not a one-time sweep.